Affiliation:
1. Department of Biostatistics, School of Public Health, Peking University, Beijing 100191, China
2. Department of Statistics, Abdul Wali Khan University, Mardan 23200, Pakistan
3. Chongqing Research Institute of Big Data, Peking University, Chongqing 401121, China
Abstract
(1) Background: The evidence indicates that comorbidities are associated with an increase in the risk of death from coronavirus disease 2019 (COVID-19). It is unclear whether such an association is different for various combinations of chronic disease comorbidities. (2) Methods: From 16 March 2020 to 30 November 2021, 104,753 patients with confirmed COVID-19 from Khyber Pakhtunkhwa Province, Pakistan, were studied to determine the association between comorbidities and the duration from symptom onset to death in patients with COVID-19 by stratifying their comorbidity status. (3) Results: The patients with comorbidities had an 84% (OR, 0.16; 95% CI, 0.14 to 0.17) decrease in the duration from symptom onset to death, as opposed to patients without a comorbidity. Among the patients with only one comorbidity, chronic lung disease (OR, 0.06; 95% CI, 0.03 to 0.09) had a greater impact on the duration from symptom onset to death than hypertension (OR, 0.15; 95% CI, 0.13 to 0.18) or diabetes (OR, 0.15; 95% CI, 0.12 to 0.18). The patients with both hypertension and diabetes had the shortest duration (OR, 0.17; 95% CI, 0.14 to 0.20) among the patients with two comorbidities. (4) Conclusions: Comorbidity yielded significant adverse impacts on the duration from symptom onset to death in COVID-19 patients in Pakistan. The impact varied with different combinations of chronic disease comorbidities in terms of the number and type of comorbidities.
Funder
National Natural Science Foundation of China
Beijing Natural Science Foundation
Fundamental Research Funds for the Central Universities
PKU-Baidu Fund
Research and Development Funds of Peking University People’s Hospital
Reference38 articles.
1. A Novel Coronavirus from Patients with Pneumonia in China, 2019;Zhu;N. Engl. J. Med.,2020
2. World Health Organization (2023, August 18). WHO Coronavirus (COVID-19) Dashboard. Available online: https://covid19.who.int/?gclid=CjwKCAiA57D_BRAZEiwAZcfCxWQWth4sNqEZ1J34KInDRNOjiLuwzkFwpDNCU7V2CPqCPGDU2jLYfhoCb6UQAvD_BwE.
3. A systematic review and meta-analysis of geographic differences in comorbidities and associated severity and mortality among individuals with COVID-19;Thakur;Sci. Rep.,2021
4. Clinical Characteristics, Mortality and Associated risk factors in COVID-19 patients reported in ten major hospitals of Khyber Pakhtunkhwa, Pakistan;Shahzad;J. Ayub Med. Coll. Abbottabad,2020
5. The potential association between common comorbidities and severity and mortality of coronavirus disease 2019: A pooled analysis;Luo;Clin. Cardiol.,2020